Healthpeak Options Turn Defensive on Earnings Day

DOC options positioning has shifted more sharply into protective territory than at any point in recent months, even as short sellers have been quietly stepping back from their positions.

The put/call ratio jumped to 0.52 on November 2, more than two standard deviations above its 20-day average of 0.42. That is the most defensive options posture DOC has seen in this run, sitting well above the midpoint of the 52-week range of 0.20 to 1.59. The move is notable because it coincides with a broader short seller retreat: short interest has dropped 7% over the past week and 5% over the past month, leaving bears holding roughly 3.1% of the free float. Borrow availability remains extraordinarily loose at 2,765% of current short interest, with a cost to borrow of just 0.46%. The short score has also eased, falling from 42.2 on October 19 to 36.7 as of October 30. The divergence between options caution and a retreating short base is the defining tension in the positioning picture.

Analyst sentiment has moved in one direction since mid-October: targets down, ratings held. Wells Fargo cut its target from $22 to $19 on October 19, keeping an Equal-Weight rating. Barclays trimmed from $24 to $21 on October 13, also maintaining its Equal-Weight view. UBS took its number from $21.50 to $20. The consensus mean target of $22.39 sits roughly 15% above the current $19.48 close, which on paper implies upside, but the direction of travel in analyst adjustments contradicts that implied optimism. The bear case centres on lab tenant credit risk, weak leasing momentum, and a FFOPS growth outlook that has been revised toward flat to slightly negative through 2027. The bull case rests on roughly 700 properties across medical office and life science, and a development pipeline that is approximately 80% pre-leased with mid-7% stabilised yields targeted.

Wikipedia attention data from the Wikimedia Foundation shows DOC drawing retail interest well above its own 90-day norm, with a z-score of 2.44 as of October 22. This is an attention signal, not a revenue indicator, and no alt data dataset for DOC has been measured to lead the company's reported figures.

The two most recent earnings reactions both ran negative: DOC fell 1.7% in the session after the August 6 release and lost 4.5% over the following five days, while the prior print produced a similar pattern of a 2.4% single-day drop and a 4.4% five-day decline. The print today will test whether the lab-leasing weakness that drove analyst target reductions has stabilised, or whether occupancy trends have deteriorated further into year-end.